研報掘金丨華源證券:昂利康業績有望重回增長軌道,首予“買入”評級
華源證券研報指出,左益集採影響逐步出清,隨着新品陸續上市推廣,昂利康業績有望重回增長軌道。公司創新轉型步伐堅定,引進親合力ALK-N001(DXd)打開想象空間。公司在心血管類製劑、口服頭孢類抗生素原料藥、alpha酮酸原料藥、吸入用麻醉原料藥、抗雄性激素中間體及植物源膽固醇系列產品上優勢顯著。另外,公司大單品左益國採影響逐步消化,隨新品陸續上市、放量,業績有望企穩回升。公司佈局植物膽固醇、動保等新領域,打造新增長極。選擇與公司同為原料藥製劑一體化企業的華納藥廠、天宇股份、司太立為可比公司,考慮公司抗腫瘤創新藥ALK-N001臨牀價值較高,業績有望觸底反彈,首次覆蓋,給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.